The tape
Trading volume across the monitored list of 10 technology and healthcare stocks showed a clear bearish tilt on Wednesday. Of the 10 tickers tracked, 7 closed in negative territory, while only 3 managed to post gains.
The technology sector bore the brunt of the selling pressure, led by significant declines in hardware and chip-related equities. Healthcare names also saw moderate weakness, with Moderna (MRNA) and Cytokinetics (CYTK) both finishing the session lower.
The buy-to-sell ratio among tracked analysts currently sits at 10 buys to 9 sells across the cohort. This narrow margin reflects the ongoing uncertainty regarding valuation multiples in the current high-interest-rate environment.
- Total tickers tracked: 10
- Gainers: 3 (MSFT, APP, PLTR)
- Decliners: 7 (MRVL, CYTK, CRCL, ASTS, NVDA, NBIS, MRNA)
- Sector performance: Technology -2.3% average; Healthcare -5.4% average
Most bought
Investors showed a preference for established software and communication platforms, favoring companies with diversified revenue streams. Microsoft (MSFT) and Applovin (APP) were the primary beneficiaries of capital rotation during the session.
Analysts remain constructive on these names, citing strong enterprise demand and improving margins. The following list summarizes the most bought assets based on current analyst consensus and price action.
- Microsoft (MSFT): 1 buy, 0 sells; price rose 1.68% to $513.53.
- Applovin (APP): 1 buy, 0 sells; price rose 1.64% to $317.76.
- Palantir (PLTR): 1 buy, 2 sells; price rose 0.19% to $186.29.
- Ast Spacemobile (ASTS): 1 buy, 0 sells; price fell 5.52% to $58.05.
Most sold
Semiconductor and high-beta technology stocks faced intense selling pressure as investors locked in profits or exited positions following disappointing guidance. Marvell Technology (MRVL) led the decline, followed by Cytokinetics (CYTK) and Circle Internet Group (CRCL).
The selling activity suggests a shift in risk appetite, with institutional investors moving away from names that failed to provide clear visibility on future revenue growth. The following tickers saw the most significant negative sentiment from analysts and market participants.
- Marvell Technology (MRVL): 2 buys, 1 sell; price fell 10.28% to $216.62.
- Cytokinetics (CYTK): 1 buy, 0 sells; price fell 7.46% to $72.09.
- Circle Internet Group (CRCL): 1 buy, 1 sell; price fell 7.53% to $87.14.
- NVIDIA (NVDA): 2 buys, 2 sells; price fell 4.57% to $217.55.
- Nebius Group (NBIS): 0 buys, 2 sells; price fell 4.26% to $209.18.
Why it moved
Marvell Technology (MRVL) shares experienced a sharp decline as investors reacted to fiscal 2028 guidance that failed to exceed high expectations. According to The Motley Fool and StockStory, the market is seeking more clarity on the timing of revenue contributions from the newly announced Google custom AI chip partnership.
The lack of a concrete timeline for the Google deal has created a valuation gap for many institutional holders. Investors are now waiting for management to provide more granular detail on how these partnerships will impact earnings per share over the next 24 months.